AU2013292040B2 - Status of tuberculosis infection in an individual - Google Patents
Status of tuberculosis infection in an individual Download PDFInfo
- Publication number
- AU2013292040B2 AU2013292040B2 AU2013292040A AU2013292040A AU2013292040B2 AU 2013292040 B2 AU2013292040 B2 AU 2013292040B2 AU 2013292040 A AU2013292040 A AU 2013292040A AU 2013292040 A AU2013292040 A AU 2013292040A AU 2013292040 B2 AU2013292040 B2 AU 2013292040B2
- Authority
- AU
- Australia
- Prior art keywords
- individual
- level
- mononuclear cells
- tuberculosis infection
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 144
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 238000012544 monitoring process Methods 0.000 claims abstract description 10
- 238000011285 therapeutic regimen Methods 0.000 claims abstract description 10
- 238000013517 stratification Methods 0.000 claims abstract description 8
- 230000008859 change Effects 0.000 claims abstract description 7
- 210000005087 mononuclear cell Anatomy 0.000 claims description 68
- 108010031025 Alanine Dehydrogenase Proteins 0.000 claims description 67
- 108090000695 Cytokines Proteins 0.000 claims description 54
- 102000004127 Cytokines Human genes 0.000 claims description 54
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 29
- 108010002350 Interleukin-2 Proteins 0.000 claims description 26
- 230000000638 stimulation Effects 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 25
- 238000003556 assay Methods 0.000 claims description 18
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 16
- 108010074328 Interferon-gamma Proteins 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 claims description 12
- 230000007704 transition Effects 0.000 claims description 11
- 238000002965 ELISA Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000009004 PCR Kit Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 9
- 101900287970 Mycobacterium tuberculosis Alanine dehydrogenase Proteins 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 238000011998 interferon-gamma release assay Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 208000033353 latent tuberculosis infection Diseases 0.000 description 11
- 206010065048 Latent tuberculosis Diseases 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 208000036981 active tuberculosis Diseases 0.000 description 9
- 238000011510 Elispot assay Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- 229960001005 tuberculin Drugs 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000020545 Exposure to communicable disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- -1 H1 hybrid Proteins 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 101100395578 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hrp1 gene Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010051837 Skin induration Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012729 kappa analysis Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90611—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general
- G01N2333/90616—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general with a definite EC number (1.4.1.-)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176506.9 | 2012-07-16 | ||
| EP12176506.9A EP2687848A1 (en) | 2012-07-16 | 2012-07-16 | Status of tuberculosis infection in an individual |
| PCT/EP2013/065002 WO2014012928A1 (en) | 2012-07-16 | 2013-07-16 | Status of tuberculosis infection in an individual |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013292040A1 AU2013292040A1 (en) | 2015-02-05 |
| AU2013292040B2 true AU2013292040B2 (en) | 2018-07-12 |
Family
ID=48795573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013292040A Ceased AU2013292040B2 (en) | 2012-07-16 | 2013-07-16 | Status of tuberculosis infection in an individual |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP2687848A1 (enExample) |
| CN (1) | CN104541169B (enExample) |
| AU (1) | AU2013292040B2 (enExample) |
| CA (1) | CA2878497C (enExample) |
| DK (1) | DK2872896T3 (enExample) |
| EA (1) | EA030721B1 (enExample) |
| ES (1) | ES2666073T3 (enExample) |
| IN (1) | IN2015MN00140A (enExample) |
| NO (1) | NO2872896T3 (enExample) |
| PL (1) | PL2872896T3 (enExample) |
| PT (1) | PT2872896T (enExample) |
| WO (1) | WO2014012928A1 (enExample) |
| ZA (1) | ZA201500254B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3171170A1 (en) * | 2015-11-17 | 2017-05-24 | Lionex GmbH | Device for use in elispot |
| KR20180104038A (ko) * | 2016-01-20 | 2018-09-19 | 시아먼 유니버시티 | 활동성 결핵의 진단을 위한 방법 및 키트 |
| CN106501530A (zh) * | 2017-01-05 | 2017-03-15 | 复旦大学附属华山医院 | 一种诊断结核杆菌感染的生物标志物及其相关试剂盒 |
| RU2726789C1 (ru) * | 2020-01-17 | 2020-07-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ФПИ" Минздрава России) | Способ иммунологического определения активности туберкулезной инфекции у детей и подростков с латентной инфекцией |
| CN115598353B (zh) * | 2022-10-24 | 2024-09-13 | 首都医科大学附属北京胸科医院 | 细胞因子作为标记物在制备肺外结核诊断或治疗预后产品中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070026473A1 (en) * | 2005-07-26 | 2007-02-01 | Gennaro Maria L | Antibody profiles characteristic of tuberculosis state |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| CA2279255A1 (en) | 1997-01-29 | 1998-08-20 | Flohe, Leopold | Test kit for tuberculosis diagnosis by determining alanine dehydrogenase |
| DE102007052518A1 (de) * | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen |
| CN102033129A (zh) * | 2009-09-29 | 2011-04-27 | 上海英伯肯医学生物技术有限公司 | 用抗原刺激的细胞免疫反应来检测病原微生物的方法及测试笔 |
-
2012
- 2012-07-16 EP EP12176506.9A patent/EP2687848A1/en not_active Withdrawn
-
2013
- 2013-07-16 EA EA201590220A patent/EA030721B1/ru not_active IP Right Cessation
- 2013-07-16 PT PT137378311T patent/PT2872896T/pt unknown
- 2013-07-16 DK DK13737831.1T patent/DK2872896T3/en active
- 2013-07-16 NO NO13737831A patent/NO2872896T3/no unknown
- 2013-07-16 WO PCT/EP2013/065002 patent/WO2014012928A1/en not_active Ceased
- 2013-07-16 IN IN140MUN2015 patent/IN2015MN00140A/en unknown
- 2013-07-16 EP EP13737831.1A patent/EP2872896B1/en active Active
- 2013-07-16 CA CA2878497A patent/CA2878497C/en not_active Expired - Fee Related
- 2013-07-16 AU AU2013292040A patent/AU2013292040B2/en not_active Ceased
- 2013-07-16 CN CN201380038250.8A patent/CN104541169B/zh not_active Expired - Fee Related
- 2013-07-16 ES ES13737831.1T patent/ES2666073T3/es active Active
- 2013-07-16 PL PL13737831T patent/PL2872896T3/pl unknown
-
2015
- 2015-01-14 ZA ZA2015/00254A patent/ZA201500254B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070026473A1 (en) * | 2005-07-26 | 2007-02-01 | Gennaro Maria L | Antibody profiles characteristic of tuberculosis state |
Non-Patent Citations (1)
| Title |
|---|
| M. L. Gennaro,et al, "Antibody markers of incident tuberculosis among HIV-infected", INT J TUBERC LUNG DIS, (2007-12-31), vol. 11, no. 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014012928A1 (en) | 2014-01-23 |
| EP2687848A1 (en) | 2014-01-22 |
| CN104541169A (zh) | 2015-04-22 |
| NO2872896T3 (enExample) | 2018-05-26 |
| ZA201500254B (en) | 2016-06-29 |
| PL2872896T3 (pl) | 2018-08-31 |
| DK2872896T3 (en) | 2018-04-09 |
| EA201590220A1 (ru) | 2015-06-30 |
| PT2872896T (pt) | 2018-04-02 |
| CA2878497C (en) | 2021-06-08 |
| EP2872896B1 (en) | 2017-12-27 |
| ES2666073T3 (es) | 2018-04-30 |
| EP2872896A1 (en) | 2015-05-20 |
| CA2878497A1 (en) | 2014-01-23 |
| EA030721B1 (ru) | 2018-09-28 |
| IN2015MN00140A (enExample) | 2015-10-16 |
| CN104541169B (zh) | 2017-09-15 |
| AU2013292040A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lighter et al. | Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children | |
| Hur et al. | Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects | |
| Clifford et al. | Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting | |
| JP5925184B2 (ja) | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染と関連した患者状況のｉｎｖｉｔｒｏ迅速判定法 | |
| AU2013292040B2 (en) | Status of tuberculosis infection in an individual | |
| Goletti et al. | IFN-γ, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis | |
| US20150153361A1 (en) | Status of Tuberculosis Infection in an Individual | |
| Coad et al. | Simultaneous measurement of antigen-induced CXCL10 and IFN-γ enhances test sensitivity for bovine TB detection in cattle | |
| CN111443208B (zh) | 鉴别活动性结核病和潜伏性结核病的组合物 | |
| Zhu et al. | Performance evaluation of IGRA-ELISA and T-SPOT. TB for diagnosing tuberculosis infection. | |
| Ren et al. | Antigen-specific chemokine profiles as biomarkers for detecting Mycobacterium tuberculosis infection | |
| KR101805250B1 (ko) | 한국 결핵균주 항원 특이적 면역반응을 이용한 결핵진단 방법 및 키트 | |
| Jeong et al. | Predictive factors for indeterminate result on the QuantiFERON test in an intermediate tuberculosis-burden country | |
| Shaikh et al. | Novel interferon-gamma assays for diagnosing tuberculosis in young children in India | |
| CN114563576B (zh) | Cxcl14作为生物标志物在结核病诊断中的用途 | |
| CN106405107A (zh) | 结核分枝杆菌抗原蛋白Rv2941及其T细胞表位肽的应用 | |
| RU2576833C1 (ru) | Способ диагностики туберкулеза и дифференциальной диагностики туберкулеза и латентной туберкулезной инфекции | |
| CN106248936B (zh) | 结核分枝杆菌抗原蛋白Rv2201及其T细胞表位肽的应用 | |
| Hernanz-Lobo et al. | Diagnostic potential of combining plasma biomarkers of tissue damage and inflammation in pediatric TB | |
| EP2711706A1 (en) | Mycobacterial thiolperoxidase and its use | |
| Firmanti et al. | Interferon-g-inducible protein 10 for diagnosis of tuberculosis in children | |
| Zaida et al. | Im-mune Biomarker Combinations for Diagnosis Monitoring of Latent Tuberculosis Infection | |
| Mi et al. | Combined detection of T cell number secreting IFN-γ and IL-2 in different tuberculosis populations and their clinical value | |
| Lapovets et al. | DYNAMICS OF CHANGES IN THE IMMUNE STATUS OF PATIENTS WITH ABDOMINAL TUBERCULOSIS DURING THE KOCH IMMUNOPROVOCATION TEST | |
| Fang et al. | Changes of CD27-and CD38+ in IFN-γ+ CD4+ T cells stimulated by Mycobacterium tuberculosis-specific antigen ESAT-6/CFP-10 before and after anti-tuberculosis treatment Running title: CD27-and CD38+ in IFN-γ+ CD4+ T cells for monitoring the efficacy of anti-TB treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |